Most peptides in the research market have short, murky origin stories. TB-500 is an exception. Its parent molecule, Thymosin Beta-4, traces back more than sixty years to a gland most people forget they have: the thymus. What began as immunology research in a New York laboratory in the 1960s slowly turned into one of the most studied questions in cell biology — how cells build, dismantle, and rebuild their internal scaffolding. This is the documented history, with the real names and dates, and an honest account of what is still unsettled.
What Thymosin Beta-4 is, and what “TB-500” refers to
Thymosin Beta-4 (often written Tβ4) is a small peptide of 43 amino acids found in nearly every human cell type and in high concentrations in platelets and wound fluid. Its best-characterised job is binding G-actin, the monomer form of actin, and holding a reserve of it inside the cell. Actin is the protein cells use to change shape and move, so a molecule that regulates the available actin pool sits close to the machinery of cell migration and tissue repair.
“TB-500” is a term from the research-chemical market rather than the scientific literature, and the naming is genuinely inconsistent. Some suppliers use it for full-length Thymosin Beta-4; others use it for a short synthetic fragment built around the peptide’s actin-binding motif, the sequence LKKTET (residues roughly 17–23), sometimes sold as an acetylated fragment. This ambiguity matters, because most of the human clinical work described below was done on the full molecule, not on a fragment. Anyone reading “TB-500” should treat the exact identity as something a certificate of analysis, not a product name, has to confirm.
The 1960s: a thymus extract and the first “thymosins”
The story starts in the early 1960s in the laboratory of Abraham White at the Albert Einstein College of Medicine in New York, where a postdoctoral researcher named Allan Goldstein was studying what the thymus actually does. In 1966, White and Goldstein published work in the Proceedings of the National Academy of Sciences describing a substance extracted from calf thymus that could restore immune function in animals lacking it. They gave these thymic factors a name: thymosins.
In 1972 the group moved to the University of Texas Medical Branch in Galveston, where over the following years they prepared and tested a partially purified calf-thymus preparation called thymosin fraction-5. That fraction was a mixture, and separating out its individual peptides is what eventually surfaced Thymosin Beta-4 as a distinct molecule. Its complete amino acid sequence was reported by Low, Hu, and Goldstein in 1981.
From immunology to actin: the 1980s and 1990s
For its first two decades, Thymosin Beta-4 was studied mainly as an immune-system peptide. That framing shifted at the start of the 1990s. In 1991, Safer, Elzinga, and Nachmias reported in the Journal of Biological Chemistry that Thymosin Beta-4 was identical to a previously described actin-sequestering factor from platelets. A 1992 paper in the Journal of Cell Biology then showed it sequesters the majority of monomeric actin in resting human white blood cells.
This reframed the peptide. It was no longer just a thymic immune factor; it was a principal buffer for the cell’s actin supply, and therefore tied to cytoskeletal dynamics, cell shape, and directed migration. That connection is what drew interest to it as a subject in wound-healing and tissue-repair research, since migrating cells — keratinocytes, fibroblasts, endothelial cells — all depend on rapid actin remodelling.
TB-500 and the modern research era
Through the 2000s, RegeneRx Biopharmaceuticals ran the most substantial clinical programs on Thymosin Beta-4, using the full-length molecule. These included RGN-259, a topical formulation studied for dry-eye disease across the ARISE trials, RGN-137 for dermal wounds such as pressure and venous stasis ulcers, and separate work on cardiac tissue. Results were mixed: some studies reported improvements on individual measures, but the programs did not produce a full regulatory approval for these indications.
Alongside this, a large body of preclinical literature accumulated. In animal models, researchers reported that Thymosin Beta-4 promoted cell migration and re-epithelialisation in dermal wound models and showed activity in cardiac and corneal repair studies. Recent reviews of Thymosin Beta-4 and TB-500 in tissue healing reach a consistent conclusion: the mechanistic and animal data are extensive, while robust human data remain limited. TB-500 as a synthetic fragment has far less direct clinical study behind it than the full-length peptide. It is not an approved medicine, and it is prohibited in sport by WADA. The honest summary is that this is a research compound with a deep preclinical record and a thin clinical one.
→ TB-500 Research Guide · BPC-157 Research Guide · COA available TB-500 range
Research use only
All products referenced here are supplied strictly as research compounds for in-vitro and laboratory research use only. They are not intended for human or animal use, not for consumption, and not for any diagnostic or therapeutic purpose. Every batch is third-party lab-tested for identity and purity, with a published certificate of analysis (COA) available for each product.